CNS Pharmaceuticals is a clinical-stage biotech with no approved products, no revenue, and no active pipeline. The company's two prior drug candidates — Berubicin and TPI 287, both investigational chemotherapy agents designed to cross the blood-brain barrier and treat glioblastoma multiforme — have been abandoned after clinical setbacks and are now being offered for out-licensing. CNS is in the middle of a strategic pivot, repositioning itself to build a new pipeline in neurology and oncology by identifying, acquiring, or in-licensing preclinical or clinical-stage drug candidates. As of early 2026, the company has not yet secured any new assets. The intended model is a standard clinical-stage biotech approach: in-license or acquire drug candidates, advance them through clinical development, and generate value through milestones, partnerships, or eventual commercialization. Executing this strategy is entirely dependent on CNS's ability to raise additional capital, which it has historically done through equity issuances. With roughly $7.2M in cash as of year-end 2025, management estimates the company can only fund operations into Q3 2026. CNS has eight full-time employees, including five executives hired in early 2026, and has acknowledged that if it cannot raise additional funds, it may need to cease operations.